Deputy Director for Clinical and Translational Research
Chair and Blomeyer Professor of Hematology and Oncology
co-Director, Cancer Drug Discovery, Development, and Delivery Program
Professor of Otolaryngology & Medicine and Pharmacology,
Chief Medical Officer at Winship Cancer Institute
Dr. Khuri is a clinician/researcher who focuses on developing novel targeted agents to treat and prevent cancer, with an emphasis on lung cancer. In the interview, Dr. Khuri discusses his work on the development of a drug that would target a process (called farneylation) that helps to activate a set of oncogenes.